Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)

Chia Jui Yen, Naomi Kiyota, Nobuhiro Hanai, Shunji Takahashi, Tomoya Yokota, Shigemichi Iwae, Yasushi Shimizu, Ruey Long Hong, Masahiro Goto, Jin Hyoung Kang, Wing Sum Kenneth Li, Robert L. Ferris, Maura Gillison, Toshimitsu Endo, Vijayvel Jayaprakash, Makoto Tahara

研究成果: Article同行評審

指紋 深入研究「Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)」主題。共同形成了獨特的指紋。

Medicine & Life Sciences